Groundbreaking research spearheaded by an interdisciplinary team at Shanghai Jiao Tong University School of Medicine, in collaboration with Fudan University and Xinjiang Medical University, has shed new light on UCP2’s functional impact within AML. Published in the reputable journal Genes & Diseases, this study sought to characterize the oncogenic role of UCP2 and explore its mechanistic links to branched-chain amino acid (BCAA) metabolism, which is increasingly recognized as essential in cancer cell survival and progression.

Initial bioinformatics analyses leveraging the Cancer Genome Atlas (TCGA) database revealed that UCP2 mRNA levels are markedly elevated in AML patients compared to healthy donors. This finding was substantiated by quantitative PCR assays performed on AML cell lines and primary patient samples, demonstrating a consistent overexpression of UCP2 at the transcript and protein levels. Notably, statistical correlations indicated that heightened UCP2 expression strongly associates with poorer overall survival rates and enhanced chemotherapy resistance, highlighting its potential prognostic utility.

Delving deeper, the researchers employed loss-of-function strategies to silence UCP2 in AML cell models, uncovering profound disruptions in leukemic cell biology. UCP2 knockdown resulted in a significant inhibition of cell proliferation accompanied by the induction of apoptosis. This effect was tightly linked to mitochondrial perturbations, as evidenced by increased mitochondrial mass and an upsurge in reactive oxygen species (ROS) generation, signaling a collapse in mitochondrial homeostasis critical for leukemia cell viability.

To dissect the metabolic underpinnings of these phenotypes, extensive RNA sequencing combined with metabolic mass spectrometry were performed. This robust integrative approach unveiled a strategic accumulation of branched-chain amino acids—namely leucine, isoleucine, and valine—within cells deficient in UCP2. Accumulated BCAAs were found to exacerbate intracellular oxidative stress, serving as key metabolites that potentiate ROS production and thereby impair leukemic cell fitness.

Significantly, this metabolic stress mediated by BCAAs was shown to activate the PI3K/AKT/mTOR signaling cascade, a pivotal pathway regulating cell growth, survival, and metabolism. Activation of this pathway in the context of UCP2 suppression triggered autophagic and apoptotic mechanisms, simultaneously arresting leukemogenic processes. Importantly, experimental removal of BCAAs from the culture medium was capable of rescuing leukemic cells from the cytotoxic effects of UCP2 inhibition, underscoring the metabolic dependency of AML cells on BCAA homeostasis for survival.

Translating these findings to an in vivo context, mouse xenograft models bearing human AML cells were treated with genipin, a selective pharmacological inhibitor of UCP2. Treatment resulted in a marked reduction of leukemic blasts and appreciable improvement in survival outcomes. The therapeutic efficacy of genipin was further potentiated by dietary supplementation of BCAAs, which paradoxically amplified oxidative stress to lethal levels in leukemic cells, effectively curtailing disease burden in both bone marrow and peripheral blood compartments.

This dual strategy—targeting UCP2 function alongside modulating BCAA availability—represents a novel therapeutic paradigm by exploiting the metabolic vulnerabilities of AML cells. This approach breaks new ground by demonstrating that metabolic modulation can enhance the anti-leukemic activity of mitochondrial protein inhibitors, thereby offering potential avenues for actually overcoming chemo-resistance, a significant obstacle in current AML management.

Despite these promising outcomes, the authors highlight that further preclinical and clinical studies are imperative to validate these therapeutic interventions in human subjects, refine dosing regimens, and assess long-term safety. It remains essential to thoroughly understand the systemic effects of manipulating amino acid metabolism and mitochondrial functions, given their fundamental roles in normal cellular physiology.

Moreover, the research provides exciting insight into the broader interplay between cancer metabolism and signaling networks within hematological malignancies, placing UCP2 at a critical nexus that influences proteostasis and energy balance through BCAA regulation. Targeting metabolic pathways in parallel with established oncogenic signals such as PI3K/AKT/mTOR may thus herald a new era of precision medicine in AML treatment.

In summary, this study convincingly delineates how UCP2 contributes to leukemogenesis by orchestrating branched-chain amino acid dynamics and controlling oxidative stress levels, which subsequently modulate critical survival signaling pathways. The findings pave the way for the development of innovative therapeutic agents, such as UCP2 inhibitors in combination with tailored metabolic modulation, to disrupt AML cell viability and improve patient prognosis.

As the field progresses, integrating molecular insights with translational therapeutics will be paramount to designing effective and durable treatments for AML patients who currently face limited options and dismal outcomes. The identification of UCP2 and its metabolic axis as central drivers and therapeutic targets represents a compelling leap forward in the quest to conquer this devastating blood cancer.

Subject of Research: Molecular mechanisms of UCP2 in acute myeloid leukemia (AML) progression and therapeutic targeting via branched-chain amino acid metabolism.

Article Title: Suppression of UCP2 alleviates leukemogenesis by enhancing branched-chain amino acids-induced oxidative stress via activating the PI3K/AKT/mTOR signaling pathway

Web References: https://doi.org/10.1016/j.gendis.2025.101794

References: Original research published in Genes & Diseases.

Image Credits: Agida Okohi Innocent, Yajie Shen, Yixuan Gao, Ruixin Sun, Kasimujiang Aximujiang, Zizhen Xu, Jinke Cheng, Jiao Ma

Keywords: Acute Myeloid Leukemia, UCP2, Mitochondrial Dysfunction, Branched-Chain Amino Acids, Oxidative Stress, PI3K/AKT/mTOR, Leukemogenesis, Metabolic Targeting, Genipin, Therapeutic Resistance

The investigation began with comprehensive analyses of multiple gene expression datasets, revealing that SLC6A6 is ubiquitously expressed across AML cases independent of cytogenetic abnormalities or French-American-British (FAB) classification subtypes. Notably, higher expression levels of this transporter were correlated with resistance to venetoclax, a BCL-2 inhibitor that has revolutionized AML treatment but often encounters resistance in clinical settings. This finding indicates that SLC6A6 might contribute to the metabolic adaptations that enable leukemic cells to evade therapeutic pressure.

Further dissection of AML cellular heterogeneity demonstrated that SLC6A6 expression is particularly enriched in reactive oxygen species (ROS)-low leukemia stem cells within monocytic AML subtypes. These ROS-low LSCs are clinically associated with heightened resistance to venetoclax, suggesting that the taurine transporter supports a metabolic state conducive to cell survival under oxidative stress conditions. The study also revealed that leukemic cells bearing oncogenic RAS mutations exhibit amplified SLC6A6 expression relative to wild-type cells, an association aligned with previous data linking RAS pathway activation to therapeutic resistance.

Importantly, SLC6A6 expression was found to be increased in relapsed AML cases originating from stem or progenitor cell populations, underscoring the transporter’s likely involvement in disease persistence and relapse. Collectively, these multi-faceted insights emphasize SLC6A6 as a crucial player across the AML spectrum, particularly in subsets demonstrating refractoriness to current frontline treatments.

To translate these findings into therapeutic avenues, the researchers evaluated the efficacy of small-molecule inhibitors targeting taurine uptake via SLC6A6. Two structurally distinct taurine analogues, TAG (6-aminomethyl-3-methyl-4H-1,2,4-benzothiadiazine-1,1-dioxide hydrochloride) and GES (guanidinoethyl sulphonate), demonstrated potent inhibition of taurine transport in vitro. Treatment with these compounds significantly reduced colony formation by SLC6A6-competent mouse leukemia stem cells but had no effect on SLC6A6 knockout counterparts, affirming the specificity of action.

Notably, TAG and GES administration in primary human AML cells led to a pronounced suppression of colony-forming capacity, with reductions ranging from nearly two- to twenty-fold. These inhibitory effects were remarkably selective, as normal human hematopoietic stem and progenitor cells (HSPCs), characterized by CD34 positivity, were largely unharmed, indicating a therapeutic window that might minimize hematopoietic toxicity.

Given the clinical relevance of venetoclax and the frequent resistance that hampers its efficacy, the investigators probed whether combining venetoclax with taurine transporter inhibition could synergistically impair leukemic growth. The data were compelling: venetoclax alone decreased viability and colony formation in mouse LSCs, and when combined with either TAG or GES, the reduction in colony-forming units was not just additive but synergistic, with up to a 7.2-fold decrease observed. This synergy extended to primary human AML cells, where combined treatment induced colony formation reductions of up to 150-fold, a staggering potentiation relative to single-agent effects.

To circumvent the limitations of small-molecule inhibitors in vivo, particularly their inefficiency in fully blocking taurine uptake, the team employed shRNA-mediated knockdown of SLC6A6. This genetic approach confirmed that reducing SLC6A6 expression diminished taurine uptake by over two-fold and dramatically impaired colony formation in diverse myeloid malignancy cell lines, including blast crisis chronic myeloid leukemia (bcCML), AML, and myelodysplastic syndrome (MDS) models.

Critically, in patient-derived AML samples, SLC6A6 knockdown led to a 2.3- to more than 9-fold decrease in clonogenic potential without adversely affecting normal CD34+ HSPCs. This specificity was further validated in xenograft models, where SLC6A6 suppression curtailed the engraftment of primary human AML cells by up to 40-fold, while sparing normal hematopoietic progenitors. These findings outline a clear therapeutic window for targeting TAUT selectively in leukemic versus normal hematopoietic cells.

The implications of this work are profound. It delineates a previously underappreciated metabolic axis in AML pathogenesis, rooted in taurine uptake and utilization, and positions SLC6A6 as an attractive therapeutic target. By disrupting taurine-driven metabolic pathways, leukemic stem cells are rendered vulnerable, especially when combined with existing agents like venetoclax, opening new directions for treating drug-resistant AML.

This study exemplifies the power of integrating genomic, metabolic, and functional assays to uncover actionable targets in cancer stem cells, the elusive reservoir driving relapse and treatment failure. Future research will be required to optimize TAUT inhibitors for clinical use, elucidate the precise metabolic signaling downstream of taurine uptake, and explore combination regimens that may yield durable remissions in patients with aggressive myeloid leukemia.

Ultimately, targeting metabolic dependencies such as SLC6A6 provides a promising frontier in the war against AML, offering hope to patients whose disease no longer responds to conventional therapies. As the field advances, such targeted metabolic interventions may become staples in precision oncology, refining treatment paradigms and improving survival outcomes.

—

Subject of Research: Taurine transporter SLC6A6’s role in acute myeloid leukemia metabolism and therapeutic resistance.

Article Title: Taurine from tumour niche drives glycolysis to promote leukaemogenesis.

Article References: Sharma, S., Rodems, B.J., Baker, C.D. et al. Taurine from tumour niche drives glycolysis to promote leukaemogenesis. Nature (2025). https://doi.org/10.1038/s41586-025-09018-7

Image Credits: AI Generated